Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis

You may be eligible if

• Age\>18 years
• Histologically confirmed primary colorectal cancer
• Stage IV colorectal cancer with \</= 3 metastases, up to 5cm in size.
• CT scan or MRI of the abdomen with contrast, 60days prior to enrollment
• If patient is allergic to contrast, imaging without contrast is acceptable
• Positron-Emission Tomography 60 days prior to enrollment
• No additional sites of metastasis at the time of protocol enrollment. History of other sites of metastasis that are currently controlled are acceptable.
• No malignant ascites
• At least 4 weeks from any chemotherapy
• No prior liver radiation therapy
• ECOG performance status 0-1
• Life expectancy\>3months
• Laboratory evaluations completed 60 days prior to treatment including CMP, CBC with differential, liver function test, and prothrombin time.